Q3 2025 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2025-11-17 · accession 0001214659-25-016751
$2.03B
Reported value
40
Positions
2025-09-30
Period end
The Brief · TCG Crossover Management, LLC · Q3 2025
AI · grounded in 13F
TCG Crossover Management, LLC closed its position in CDTX for a reduction of $48.99M. The fund established a new position in LQDA valued at $38.88M. Other activity included accumulating shares of ABVX by 17.419% and CNTA by 8.498%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | $603.8M | 29.7% | 7,111,596 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $147.8M | 7.27% | 3,670,206 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $97.6M | 4.80% | 6,798,162 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $84.9M | 4.17% | 6,243,812 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $76.1M | 3.74% | 3,136,480 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $71.7M | 3.53% | 8,536,196 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $71.5M | 3.52% | 6,117,232 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $66.0M | 3.25% | 1,676,624 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $62.7M | 3.09% | 1,311,783 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $58.4M | 2.87% | 4,615,144 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $57.4M | 2.82% | 1,430,041 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $50.9M | 2.50% | 3,572,335 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $48.3M | 2.38% | 5,250,000 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $44.1M | 2.17% | 12,362,205 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $42.2M | 2.08% | 1,636,275 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $40.5M | 1.99% | 2,898,103 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $39.8M | 1.96% | 2,117,103 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA TECHNOLOGIES INC | $38.9M | 1.91% | 1,710,084 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $30.7M | 1.51% | 465,257 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $29.8M | 1.46% | 1,063,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $28.8M | 1.41% | 2,452,138 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $27.6M | 1.36% | 1,745,016 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $20.4M | 1.00% | 436,473 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $20.1M | 0.99% | 2,761,861 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $19.9M | 0.98% | 416,301 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $18.8M | 0.92% | 1,145,538 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $18.4M | 0.91% | 1,100,582 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $15.7M | 0.77% | 3,033,560 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $14.3M | 0.70% | 717,347 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS HOLDING CO LLC | $13.8M | 0.68% | 1,617,365 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $12.5M | 0.61% | 153,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $11.4M | 0.56% | 650,000 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $9.5M | 0.47% | 2,676,580 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $9.5M | 0.46% | 1,810,351 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $7.6M | 0.37% | 1,668,174 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $6.1M | 0.30% | 483,000 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $5.6M | 0.27% | 1,390,175 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $5.5M | 0.27% | 1,200,000 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $3.4M | 0.17% | 584,955 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $983,366 | 0.05% | 316,195 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.